Life-Extending Breast Cancer Drug Enhertu Becomes Available on NHS in England

According to reporting by the BBC, patients in England diagnosed with a specific type of incurable breast cancer can now access the life-extending drug Enhertu on the National Health Service. The rollout comes two years after the medication was initially deemed too expensive by health evaluators.

Medical data indicates that Enhertu can provide patients with an average of nearly seven extra months of life, with some individuals living up to three years longer. The treatment specifically targets HER2-low metastatic breast cancer, a condition affecting approximately 1,000 women in England each year.

Prior to this decision, women in Scotland had already gained access to the drug on the NHS starting in 2023. Additionally, the medication is available across 26 other European countries.

Charities and patients have continuously campaigned for broader availability since 2024. That year, the National Institute for Health and Care Excellence initially concluded that Enhertu did not represent good value for money.

Beginning on a Thursday, doctors across England gained the ability to prescribe the medication. Wales is expected to follow shortly, though the current guidance does not automatically apply in Northern Ireland.

Health Secretary Yvette Cooper stated that Enhertu can be life-changing and noted that the recommendation ensures NHS patients can finally benefit from the treatment. She added that the outcome serves as a tribute to the campaigners and charities who never stopped pressing for the decision.

Despite the positive news, advocacy organizations have emphasized the human cost of the intervening delays. The charity Breast Cancer Now noted that while campaigners' persistence ultimately paid off, thousands of individuals missed out on access to Enhertu and many have died in the interim.

Claire Rowney, chief executive of Breast Cancer Now, stated that while supporters could finally celebrate, they could not ignore the devastating cost of the delay. She called on the government, NICE, NHS England, and the pharmaceutical industry to work together to fix the system so patients are not forced to spend precious time campaigning for life-extending care.

Among those affected is 51-year-old Kate Wills, who lives with HER2-low metastatic breast cancer that has spread to her bones and lungs. She described the period of knowing the drug existed but remaining unable to access it as incredibly painful.

Upon learning that Enhertu would become available on the NHS, Wills expressed immense relief and joy, explaining that the development provides her with enormous hope as she aims to stay alive long enough to watch her teenage and young adult children reach major life milestones.

At the same time, Wills acknowledged the bittersweet nature of the moment, noting her first thoughts went to friends who did not survive to see the treatment approved. Among them was Jeannie Ambrose, who campaigned for the drug before passing away in January at the age of 53.

According to the BBC, the drug companies Daiichi Sankyo and AstraZeneca did not substantially lower their prices since the initial rejection. Instead, NICE reversed its decision largely due to a trade deal with the United States in which the UK government agreed to spend 25% more on medicines.

As part of this arrangement, NICE increased the upper threshold of how much the NHS will pay for every extra year of good quality life a medication provides, known as a Quality-Adjusted Life Year, raising the limit from £30,000 to £35,000. Furthermore, NICE introduced a different, more nuanced methodology for measuring patient quality of life at the end of August.

Helen Knight, director of medicines evaluation at NICE, expressed pleasure that a commercial solution allowed the treatment to reach the NHS in England, while acknowledging that the decision arrives too late for numerous families. Representatives from AstraZeneca called for strong collaboration across the healthcare system to ensure faster and more equitable patient access in the future.